GROUPE FRANCOPHONE DES MYELODYSPLASIES

Their core work

GFM is a French-speaking clinical research group specialized in myelodysplastic syndromes (MDS) — a family of blood cancers where the bone marrow fails to produce healthy blood cells. They contribute clinical expertise, patient cohort data, and disease-specific knowledge to large European hematology consortia. Their work spans patient stratification, real-world outcome measurement, and translational research linking molecular genetics to treatment decisions in blood cancers.

What they specialise in

How they've shifted over time

GFM's trajectory shows a clear broadening from disease-specific clinical research to data-driven hematology. Their earliest project (MDS-RIGHT, 2015) focused narrowly on optimizing care for MDS patients — their core disease specialty. By 2017-2020, through HARMONY and HARMONY PLUS, they expanded into multi-disease big data platforms, digital health outcomes, and molecular genetics across all blood cancers. The trend is a move from a single-disease clinical group toward a data contributor in pan-hematology research infrastructure.

GFM is evolving from a disease-specific clinical network into a contributor to large-scale hematology data platforms, making them increasingly relevant for digital health and precision medicine initiatives in blood cancer.

How they like to work

GFM operates exclusively as a participant — they have never coordinated an H2020 project, which is typical for specialized clinical research groups that contribute domain expertise and patient data rather than managing large consortia. They work in large networks (67 unique partners across 14 countries), suggesting they are comfortable in big multi-site collaborations. Their repeat involvement in the HARMONY ecosystem (both HARMONY and HARMONY PLUS) shows they build lasting relationships within consortia rather than jumping between unrelated projects.

GFM has collaborated with 67 unique partners across 14 countries, reflecting their integration into major pan-European hematology research networks. Their network is broad but concentrated in health research, driven largely by the HARMONY mega-consortium.

What sets them apart

GFM brings deep, focused expertise in myelodysplastic syndromes — a niche but clinically important area where few organizations have comparable depth. As a francophone clinical research group, they offer access to French-speaking patient cohorts and clinical networks that are otherwise hard to reach for international consortia. Their combination of disease-specific clinical knowledge and growing experience with big data platforms makes them a valuable bridge between traditional hematology research and modern data-driven approaches.

Highlights from their portfolio

• MDS-RIGHT
  Their largest funded project (EUR 421K) and most closely aligned with GFM's core mission — directly focused on improving care pathways for MDS patients.
• HARMONY
  One of Europe's largest hematology big data initiatives, building a platform for real-life patient data across all major blood cancers with a massive multi-country consortium.
• HARMONY PLUS
  Continuation project extending HARMONY into digital health outcomes, molecular genetics, and sustainable business models for hematology data infrastructure.